Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Savara Inc.NASDAQ: SVRA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $23.4M rose 22.1% year over year, ahead of the +6.5% change in trailing-twelve-month research & development. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +42.9% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.1% holds above the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.4M+11.9% QoQ
Last fiscal yearDec 2025
$81.4M+4.3% YoY
LTMMar 2026
$85.64M+6.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.1%——
1 year+4.3%——
3-year CAGR+42.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
81.4M USD
Year-over-year change
+4.3%
4-year CAGR
+29.4%

Research & Development vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 research & development of $85.64M is the highest of the 2 companies compared; the peer median is $31.39M.
  • Its year-over-year change of +6.5% is the highest of 2, against a peer median of -21.6%.
  • Over three fiscal years its annual growth of +42.9% compares with a peer median of -18.9%.
SVRA Competitors Peer median
Research & Development for SVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVRASavara Inc.LTM Mar 2026$85.64M +6.5%+42.9%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$31.39M -21.6%-18.9%28.6%
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $31.39M-21.6%-18.9%28.6%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue28.99M27.88M44.26M78.03M245K
Gross Profit(28.99M)(27.88M)(44.26M)(78.03M)(245K)
Gross Margin—————
Research & Development28.99M27.88M44.26M78.03M81.4M
Selling, General & Admin12.35M10.93M15.67M25.04M42.06M
Operating Expenses12.49M10.96M15.75M25.17M123.3M
Depreciation & Amortization136K31K77K130K245K
EBITDA(40.5M)(38.01M)(59.13M)(102.27M)(118.59M)
EBITDA Margin—————
Operating Income(41.48M)(38.84M)(60.01M)(103.2M)(123.55M)
Operating Margin—————
Interest Income2.28K884.44M6.47M4.16M
Interest Expense2.28M88K000
Other Income / Expenses(1.54M)689K5.31M7.32M4.71M
Income Before Tax(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Net Margin—————
EPS (Basic)(0.32)(0.25)(0.33)(0.48)(0.53)
EPS (Diluted)(0.32)(0.25)(0.33)(0.48)(0.53)
Weighted Avg Shares133.92M152.77M165.2M198.19M222.39M
Weighted Avg Shares (Diluted)133.92M152.77M165.2M198.19M222.39M

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.